(S (NP (NP (JJ Model-informed) (NN precision) (NN dosing)) (PRN (-LRB- -LRB-) (NP (NNP MIPD)) (-RRB- -RRB-)) (VP (VBG using) (NP (JJ therapeutic) (NN drug/biomarker) (NN monitoring)))) (VP (VBZ offers) (NP (DT the) (NN opportunity) (S (VP (TO to) (VP (ADVP (RB significantly)) (VB improve) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NN drug) (NNS therapies))))))))) (. .))
(S (NP (JJ Current) (NNS strategies)) (VP (VP (VBP comprise) (NP (JJ model-informed) (NN dosing) (NNS tables))) (CC or) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (JJ maximum) (JJ a-posteriori) (NNS estimates)))))) (. .))
(S (NP (DT These) (NNS approaches)) (, ,) (ADVP (RB however)) (, ,) (VP (VP (VBP lack) (NP (NP (DT a) (NN quantification)) (PP (IN of) (NP (NN uncertainty))))) (NN and/or) (VP (VBP consider) (NP (NP (RB only) (NN part)) (PP (IN of) (NP (DT the) (JJ available) (JJ patient-specific) (NN information)))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (CD three) (JJ novel) (NNS approaches)) (PP (IN for) (NP (NNP MIPD))) (VP (VBG employing) (NP (NP (NP (NNP Bayesian) (NN data) (NN assimilation)) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-))) (VBP and/or) (NP (NP (JJ reinforcement) (NN learning)) (PRN (-LRB- -LRB-) (NP (NNP RL)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB control) (NP (NP (NN neutropenia)) (, ,) (NP (NP (DT the) (JJ major) (JJ dose-limiting) (NN side) (NN effect)) (PP (IN in) (NP (NN anticancer) (NN chemotherapy))))))))))) (. .))
(S (NP (DT These) (NNS approaches)) (VP (VBP have) (NP (DT the) (JJ potential) (S (VP (TO to) (VP (ADVP (RB substantially)) (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (X (ADVP (JJ life-threatening) (NN grade) (CD 4) (CC and))) (ADJP (JJ subtherapeutic) (NN grade) (CD 0)) (NN neutropenia)))) (PP (VBN compared) (PP (TO to) (NP (VBG existing) (NNS approaches))))))))) (. .))
(S (NP (PRP We)) (ADVP (VBP further)) (VP (VB show) (SBAR (IN that) (S (NP (NNP RL)) (VP (VBZ allows) (S (VP (TO to) (VP (VB gain) (NP (JJ further) (NNS insights)) (PP (IN by) (S (VP (VBG identifying) (NP (NP (JJ patient) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP drive) (NP (JJ dose) (NNS decisions)))))))))))))))) (. .))
(S (PP (JJ Due) (TO to) (NP (PRP$ its) (NN flexibility))) (, ,) (NP (DT the) (VBN proposed) (VBN combined) (NNP DA-RL) (NN approach)) (VP (MD can) (VP (ADVP (RB easily)) (VB be) (VP (VBN extended) (S (VP (TO to) (VP (VB integrate) (NP (NP (JJ multiple) (NNS endpoints)) (CC or) (NP (JJ patient-reported) (NNS outcomes)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG promising) (NP (NP (JJ important) (NNS benefits)) (PP (IN for) (NP (JJ future) (JJ personalized) (NNS therapies))))))))) (. .))
